• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus.极低的血液羟氯喹浓度作为系统性红斑狼疮治疗依从性差的客观指标。
Ann Rheum Dis. 2007 Jun;66(6):821-4. doi: 10.1136/ard.2006.067835. Epub 2007 Feb 26.
2
Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.羟氯喹水平与以西班牙裔为主的系统性红斑狼疮患者疾病活动度的相关性研究。
Lupus. 2019 Jun;28(7):862-867. doi: 10.1177/0961203319851558. Epub 2019 May 24.
3
Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease.健康状况和免疫抑制剂的联合处方是系统性红斑狼疮长期无活动疾病患者羟氯喹依从性差的风险因素。
Lupus. 2018 Feb;27(2):265-272. doi: 10.1177/0961203317717631. Epub 2017 Jun 28.
4
Adherence to treatment in systemic lupus erythematosus patients.系统性红斑狼疮患者的治疗依从性。
Best Pract Res Clin Rheumatol. 2013 Jun;27(3):329-40. doi: 10.1016/j.berh.2013.07.001.
5
Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus.系统性红斑狼疮患者血液羟氯喹浓度的相关因素
Arthritis Care Res (Hoboken). 2017 Apr;69(4):536-542. doi: 10.1002/acr.22962. Epub 2017 Mar 7.
6
Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.羟氯喹血液浓度低是系统性红斑狼疮患者疾病加重的一个标志及预测指标。
Arthritis Rheum. 2006 Oct;54(10):3284-90. doi: 10.1002/art.22156.
7
Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.监测系统性红斑狼疮患者羟氯喹水平的临床意义:系统评价和荟萃分析。
Arthritis Care Res (Hoboken). 2021 May;73(5):707-716. doi: 10.1002/acr.24155. Epub 2021 Mar 30.
8
Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.羟氯喹血药浓度在系统性红斑狼疮中的变化决定因素。
Arthritis Rheumatol. 2015 May;67(8):2176-84. doi: 10.1002/art.39194.
9
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).羟氯喹治疗红斑狼疮的多中心对照试验(PLUS 研究)结果
Ann Rheum Dis. 2013 Nov;72(11):1786-92. doi: 10.1136/annrheumdis-2012-202322. Epub 2012 Nov 10.
10
A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus.羟氯喹在系统性红斑狼疮患者中的浓度及其影响的横断面研究。
Intern Med J. 2013 May;43(5):547-53. doi: 10.1111/imj.12100.

引用本文的文献

1
Refining lupus management: a comprehensive review of HCQ blood levels.优化狼疮管理:对羟氯喹血液水平的全面综述
Rheumatol Adv Pract. 2025 Jul 7;9(3):rkaf080. doi: 10.1093/rap/rkaf080. eCollection 2025.
2
Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus.系统性红斑狼疮达标治疗策略的演变概念
Mediterr J Rheumatol. 2024 Jun 30;35(Suppl 2):328-341. doi: 10.31138/mjr.290424.eci. eCollection 2024 Jun.
3
Therapeutic Hydroxychloroquine Blood Levels Are Associated With Fewer Hospitalizations and Possible Reduction of Health Disparities in Lupus.羟氯喹的治疗血药浓度与减少狼疮患者住院治疗相关,且可能减少健康差异。
Arthritis Care Res (Hoboken). 2024 Dec;76(12):1606-1616. doi: 10.1002/acr.25422. Epub 2024 Oct 1.
4
Treatment patterns in patients with systemic lupus erythematosus in New Zealand.新西兰系统性红斑狼疮患者的治疗模式。
Lupus. 2024 Oct;33(11):1260-1273. doi: 10.1177/09612033241274911. Epub 2024 Aug 16.
5
Hydroxychloroquine levels in pregnancy and materno-fetal outcomes in systemic lupus erythematosus patients.系统性红斑狼疮患者孕期羟氯喹水平与母婴结局
Rheumatology (Oxford). 2025 Mar 1;64(3):1225-1233. doi: 10.1093/rheumatology/keae302.
6
Adherence to low-dose methotrexate in children with juvenile idiopathic arthritis using a sensitive methotrexate assay.采用敏感的甲氨蝶呤检测方法评估儿童幼年特发性关节炎患者低剂量甲氨蝶呤的依从性。
Pediatr Rheumatol Online J. 2024 May 7;22(1):52. doi: 10.1186/s12969-024-00988-y.
7
Saudi National Clinical Practice Guidelines for Management of Adult Systemic Lupus Erythematosus.沙特阿拉伯成人系统性红斑狼疮管理国家临床实践指南
Curr Rheumatol Rev. 2025;21(1):70-96. doi: 10.2174/0115733971275638240429063041.
8
Interpreting hydroxychloroquine blood levels for medication non-adherence: a pharmacokinetic study.解读羟氯喹血药浓度以评估药物不依从性:一项药代动力学研究。
Lupus Sci Med. 2024 Apr 30;11(1):e001090. doi: 10.1136/lupus-2023-001090.
9
Factors associated with non-adherence to medications in systemic lupus erythematosus: Results from a Swedish survey.与系统性红斑狼疮患者药物治疗不依从相关的因素:来自瑞典调查的结果。
Lupus. 2024 May;33(6):615-628. doi: 10.1177/09612033241242692. Epub 2024 Mar 28.
10
Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE.基因型指导的中国系统性红斑狼疮患者羟氯喹给药剂量优化新方法。
Lupus Sci Med. 2023 Nov 22;10(2):e000997. doi: 10.1136/lupus-2023-000997.

本文引用的文献

1
Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.羟氯喹血液浓度低是系统性红斑狼疮患者疾病加重的一个标志及预测指标。
Arthritis Rheum. 2006 Oct;54(10):3284-90. doi: 10.1002/art.22156.
2
Azathioprine and inhibition of the anticoagulant effect of warfarin: evidence from a case report and a literature review.硫唑嘌呤与华法林抗凝作用的抑制:来自一例病例报告及文献综述的证据
Am J Geriatr Pharmacother. 2006 Mar;4(1):75-7. doi: 10.1016/j.amjopharm.2006.03.001.
3
Adherence to medication.药物依从性
N Engl J Med. 2005 Aug 4;353(5):487-97. doi: 10.1056/NEJMra050100.
4
Systemic lupus erythematosus in three ethnic groups. XVIII. Factors predictive of poor compliance with study visits.三个种族群体中的系统性红斑狼疮。第十八部分:预测研究访视依从性差的因素。
Arthritis Rheum. 2004 Apr 15;51(2):258-63. doi: 10.1002/art.20226.
5
Compliance: the patient, the doctor, and the medication?依从性:患者、医生与药物?
Transplantation. 2004 Mar 15;77(5):782-6. doi: 10.1097/01.tp.0000110411.23547.d4.
6
Barriers to treatment adherence among African American and white women with systemic lupus erythematosus.患有系统性红斑狼疮的非裔美国女性和白人女性在治疗依从性方面的障碍。
Arthritis Rheum. 2002 Dec 15;47(6):630-8. doi: 10.1002/art.10790.
7
Interventions to enhance patient adherence to medication prescriptions: scientific review.提高患者对药物处方依从性的干预措施:科学综述
JAMA. 2002 Dec 11;288(22):2868-79. doi: 10.1001/jama.288.22.2868.
8
Compliance with drug therapy-new answers to an old question.药物治疗的依从性——一个老问题的新答案。
Nephrol Dial Transplant. 2001 Jul;16(7):1317-21. doi: 10.1093/ndt/16.7.1317.
9
Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study.急诊室中的狼疮患者。就诊原因、住院情况及结局。一项队列研究。
Lupus. 2000;9(8):601-6. doi: 10.1191/096120300678828785.
10
Lost-to-follow-up study in systemic lupus erythematosus (SLE).系统性红斑狼疮(SLE)失访研究。
Lupus. 2000;9(5):363-7. doi: 10.1191/096120300678828325.

极低的血液羟氯喹浓度作为系统性红斑狼疮治疗依从性差的客观指标。

Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus.

作者信息

Costedoat-Chalumeau Nathalie, Amoura Zahir, Hulot Jean-Sébastien, Aymard Guy, Leroux Gaëlle, Marra Donata, Lechat Philippe, Piette Jean-Charles

机构信息

AP-HP, Service de Médecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, CHU Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France.

出版信息

Ann Rheum Dis. 2007 Jun;66(6):821-4. doi: 10.1136/ard.2006.067835. Epub 2007 Feb 26.

DOI:10.1136/ard.2006.067835
PMID:17324970
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1954674/
Abstract

BACKGROUND

Poor adherence to treatment is difficult to diagnose accurately. Hydroxychloroquine (HCQ) has a long elimination half-life and its concentration in whole blood can be measured easily.

OBJECTIVE

To evaluate the utility of a very low blood HCQ concentration as a marker of poor compliance in patients with systemic lupus erythematosus (SLE).

METHODS

HCQ concentrations were determined on a blinded basis in 203 unselected patients with SLE. At the end of the study, the patients were informed of the results and retrospectively interviewed about their adherence to treatment.

RESULTS

14 (7%) patients said that they had stopped taking HCQ (n = 8) or had taken it no more than once or twice a week (n = 6). Their mean (SD) HCQ concentration was 26 (46) ng/ml. range (0-129 ng/ml) By contrast, the other patients had a mean HCQ concentration of 1079 ng/ml range (205-2629 ng/ml). The principal barriers to adherence were related to HCQ treatment characteristics. Adherence subsequently improved in 10 of the 12 patients whose blood HCQ concentrations were remeasured.

CONCLUSIONS

Very low whole-blood HCQ concentrations are an objective marker of prolonged poor compliance in patients with SLE. Regular drug assays might help doctors in detect non-compliance and serve as a basis for counselling and supporting these patients.

摘要

背景

治疗依从性差难以准确诊断。羟氯喹(HCQ)消除半衰期长,且全血中其浓度易于测定。

目的

评估极低的血液HCQ浓度作为系统性红斑狼疮(SLE)患者依从性差的标志物的效用。

方法

对203例未经挑选的SLE患者进行盲法测定HCQ浓度。研究结束时,告知患者结果,并对其治疗依从性进行回顾性访谈。

结果

14例(7%)患者表示已停止服用HCQ(8例)或每周服用不超过一两次(6例)。他们的平均(标准差)HCQ浓度为26(46)纳克/毫升,范围(0 - 129纳克/毫升)。相比之下,其他患者的平均HCQ浓度为1079纳克/毫升,范围(205 - 2629纳克/毫升)。依从性的主要障碍与HCQ治疗特点有关。在重新测定血液HCQ浓度的12例患者中,有10例的依从性随后得到改善。

结论

极低的全血HCQ浓度是SLE患者长期依从性差的客观标志物。定期药物检测可能有助于医生发现不依从情况,并作为为这些患者提供咨询和支持的依据。